Observational studyCentral European journal of public health2026
Cytisine for smoking cessation in clinical practice: a retrospective analysis of early outcomes in Türkiye.
Observational study in Central European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSmoking remains a major global public health problem, and pharmacological therapies are central to cessation strategies. Cytisine, a plant-derived alkaloid, has recently been introduced in Türkiye as a smoking cessation aid. This study aimed to evaluate the early effectiveness and cessation outcomes of cytisine in a Turkish population.
methodsThis retrospective observational study included 289 patients who were prescribed cytisine at a smoking cessation clinic between March and May 2024. Socio-demographic characteristics, smoking history, nicotine dependence, treatment duration, and smoking cessation outcomes at 1 month and 6 months were analysed. Smoking cessation status was self-reported. Analyses were conducted using the intention-to-treat principle, with participants lost to follow-up classified as non-quitters.
resultsCytisine was prescribed according to the national 25-day tapering regimen, and the actual duration of use was recorded. In the intention-to-treat population, smoking cessation was achieved by 42.6% of participants at 1 month and by 39.8% at 6 months. At both follow-up points, participants who quit smoking were younger and had shorter smoking duration and lower cumulative smoking exposure. Higher educational attainment was associated with greater cessation success, whereas sex, marital status, chronic disease, daily cigarette consumption, smoking exposure, previous quit attempts, and baseline nicotine dependence were not. In multivariable analyses, higher educational level independently reduced the likelihood of cessation failure at 1 month (adjusted odds ratio = 0.52, 95% CI: 0.29-0.96), while longer duration of cytisine use was independently associated with greater smoking cessation success at 6 months, with each additional treatment day increasing the odds of cessation by approximately 15.0% (aOR = 1.15, 95% CI: 1.10-1.19, p < 0.001).
conclusionsCytisine showed promising early effectiveness as a smoking cessation aid in Türkiye. Treatment adherence appears to be a key determinant of cessation success, supporting its potential role in national smoking cessation programmes.
Indexed as
Identifiers
42444432What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.